Varicella-zoster virus (strain Oka vaccine) Envelope glycoprotein E Protein

Cat. No. VZV-VM10E

Description

Source	Recombinant Varicella-zoster virus (strain Oka vaccine) Envelope glycoprotein E Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Ser31-Tyr538.
Accession	Q9J3M8
Molecular Weight	The protein has a predicted MW of 58.39 kDa. Due to glycosylation, the protein migrates to 65-85 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

VZV glycoprotein E (gE) is most abundantly expressed on the surface of infected cells, and is an essential component for virus replication and cell-to-cell transmission. It is also the main target of virus-specific antibodies and T cell responses that is often selected as vaccine candidate antigen.

Assay Data

Bis-Tris PAGE



Varicella-zoster virus (strain Oka vaccine) Envelope glycoprotein E on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Varicella-zoster virus (strain Oka vaccine) Envelope glycoprotein E Protein

Cat. No. VZV-VM10E

Assay Data



The purity of Varicella-zoster virus (strain Oka vaccine) Envelope glycoprotein E is greater than 95% as determined by SEC-HPLC.